IMpower130, a multicenter phase 3 RCT, evaluated the efficacy of atezolizumab plus carboplatin plus nanoparticle albumin-bound (nab)-paclitaxel versus chemotherapy in patients with metastatic non-squamous NSCLC without EGFR mutations or ALK rearrangements, according of PD-L1 tumor expression. Here, ALK is linked to non-small cell lung carcinoma.